Tag: VIVA 2019
VIVA keynote: Medical education needs a reboot in the digital age
Introduced as “a pioneer in the vascular arena”, Michael Dake, senior vice president of the University of Arizona Health Sciences, Tucson, USA, addressed the...
EXTRACT-PE an “important first study” for aspiration thrombectomy in acute PE...
Akhilesh Sista (New York, USA) talks to Interventional News at VIVA 2019 (Vascular InterVentional Advances; 4–7 November, Las Vegas, USA) about the results of the EXTRACT-PE study, that were presented in a late-breaking...
With national regulatory approaches diverging, FDA urges “global consensus” at VIVA
Many regulatory jurisdictions are establishing different approaches for medical devices, Misti Malone, assistant director in the Office of Cardiovascular Devices at the US Food...
Endovascular arteriovenous fistulas “key part of any dialysis programme”
Endovascular arteriovenous fistulas (endoAVF) platforms add additional fistula options for patients and physicians, argues Dheeraj Rajan (University Health Network, University of Toronto, Toronto, Canada,...
VIVA 2019: SELUTION sirolimus DCB safe and effective through two years
The SELUTION SFA trial met its primary endpoint and demonstrated an late lumen loss of 0.19mm. Furthermore, excellent freedom from clinically driven TLR was...
VIVA 2019: Four-Year data from the IN.PACT Global study highlight durable...
Medtronic today announced four-year data from the IN.PACT Global study, which reinforce the long-term durability and safety of the IN.PACT Admiral drug-coated balloon (DCB)...
VIVA 2019: Boston Scientific announces positive data for the Ranger DCB...
Boston Scientific today announced positive data for two devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical trial presentations at the 2019...
VIVA 2019: Revolutions system meets primary and safety endpoints in REVEAL...
Findings from the REVEAL study confirm a favourable safety and effectiveness profile through six months for the Revolution peripheral atherectomy system from Rex Medical....
VIVA 2019: One-year freedom from clinically-driven target lesion revascularisation in MIMICS-3D...
One-year results of the MIMICS-3D study were announced today at the 2019 Vascular Interventional Advances conference (VIVA; 4–7 November, Las Vegas, USA). Freedom from...
VIVA 2019: Temporary Spur stent system appears to be feasible and...
Today at the 2019 Vascular Interventional Advances conference (VIVA; 4–7 November, Las Vegas, USA), Thomas Zeller (Bad Krozingen, Germany) gave an update on the...
VIVA 2019: TOBA II BTK meets primary safety and efficacy endpoints...
It was announced today at the 2019 Vascular Interventional Advances conference (VIVA) (4–7 November, Las Vegas, USA) that, through six months, TOBA II BTK...
VIVA 2019: ABSORB BVS achieves “excellent” long-term patency and freedom from...
Ramon Varcoe today announced positive five-year results of the ABSORB BTK trial at the 2019 Vascular Interventional Advances conference (VIVA) in Las Vegas, USA...
VIVA 2019: LimFlow announces positive six-month data From PROMISE I US...
LimFlow SA today announced the presentation of positive six-month data from the full patient cohort in its PROMISE I early feasibility study of the...
VIVA 2019: Perivascular temsirolimus could be “viable alternative” to prevent restenosis...
It was announced today that results of the TANGO low-dose cohort compared to controls are positive, both for primary and secondary endpoints. These latest...
VIVA 2019: Ultrasound before angioplasty for BTK lesions may improve outcomes...
Low-frequency, high-intensity ultrasound energy delivery followed by percutaneous transluminal angioplasty (PTA) may improve clinical outcomes in below-the-knee (BTK) lesions without the need for a...
VIVA 2019: Penumbra Indigo Aspiration system IDE trial for acute PE...
Penumbra today announced that the EXTRACT-PE trial successfully met the primary endpoints, demonstrating the safety and efficacy of the Indigo Aspiration system for aspiration...
VIVA 2019: Zilver PTX shows benefits across different patient groups
At this year’s Vascular Interventional Advances (VIVA) conference (4–7 November, Las Vegas, USA), Michael D Dake presented data on Zilver PTX that supports the...
